Bristol Myers Squibb Company $BMY Stock: Curated Wealth Partners LLC Cuts Position

Curated Wealth Partners LLC trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 67.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,635 shares of the biopharmaceutical company’s stock after selling 54,528 shares during the quarter. Curated Wealth Partners LLC’s holdings in Bristol Myers Squibb were worth $1,662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Davis Asset Management L.P. purchased a new position in shares of Bristol Myers Squibb during the second quarter worth $27,000. Addison Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter worth about $32,000. Bayban purchased a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $31,000. Groupe la Francaise raised its holdings in shares of Bristol Myers Squibb by 562.9% during the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 501 shares during the last quarter. Finally, Kilter Group LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $35,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.05% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on BMY shares. Guggenheim reissued a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Rothschild & Co Redburn upped their target price on shares of Bristol Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. raised their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. TD Cowen assumed coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating for the company. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $76.00 price objective on shares of Bristol Myers Squibb in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $64.88.

Bristol Myers Squibb Stock Performance

Shares of BMY stock traded up $1.83 during midday trading on Thursday, hitting $61.11. The company had a trading volume of 5,578,121 shares, compared to its average volume of 12,057,397. The stock has a market cap of $124.83 billion, a price-to-earnings ratio of 13.46, a PEG ratio of 0.28 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The company’s 50 day simple moving average is $63.72 and its 200 day simple moving average is $60.28.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.70 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers reported encouraging Phase 3 data for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, including an improvement in progression-free survival. The results could support upcoming regulatory discussions and strengthen the company’s oncology pipeline. What Could Bristol Myers Squibb Two Phase 3 Wins Change?
• Positive Sentiment: Additional late-stage results for admilparant in idiopathic pulmonary fibrosis were described as showing meaningful clinical benefits and a favorable safety profile. If confirmed, the program could add a new growth opportunity beyond Bristol Myers’ established products. Phase 3 Wins
• Positive Sentiment: Truist maintained a Buy rating, while several articles highlighted BMY’s relatively modest valuation, income potential and history of maintaining dividends through difficult market conditions. Its valuation metrics include a P/E near 13.5 and a PEG ratio below 0.3. Truist Buy Rating
• Neutral Sentiment: BMY became a heavily searched or “trending” stock on Zacks, increasing visibility but providing no fundamental change by itself. Analysts’ opinions remain mixed across comparisons with other healthcare companies. Trending Stock Analysis
• Negative Sentiment: Other coverage characterized the admilparant Phase 3 results as mixed, creating uncertainty about the drug’s ultimate approval prospects and commercial contribution. Investors must also weigh long-term patent expirations and competition affecting blockbuster medicines. Mixed Phase 3 Trial Results

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.